Research from Best Practices, LLC Delivers Blueprint for New Product Planning Success

CHAPEL HILL, N.C., April 6 /PRNewswire/ -- With patent clocks ticking away, pharmaceutical and biotech companies are under pressure to deliver new products in shorter time frames. Key to that effort is the New Product Planning function, which seeds the development cycle with commercial insights to help drive not only the development process but also a successful launch.

A wide-ranging benchmarking study from Best Practices, LLC provides managers and executives in new product planning (NPP) with actionable insights into critical aspects of the function, such as coordinating regional and global NPP efforts and carrying out dozens of activities that generate commercial insights. To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr993.htm.

Regarding global/regional NPP coordination, the report found:

• To ensure regional NPP representatives have a voice to bring local perspectives to the development process, one benchmarked company creates global NPP teams for each compound. It has team leaders from three major regions (U.S., Europe and Asia) and a global coordinator is assigned to oversee the group and its findings/recommendations to global senior management at HQ.

Regarding Market Research activities, the report found:

• Pre-clinical is viewed as the most crucial stage for Market Research. That is when NPP teams use Market Research to understand the unmet medical need, what market position will be sought and how you will differentiate your product. In the pre-clinical stage - before clinical data is available - it is critical to focus Market Research Activities on understanding what options exist in the marketplace and if a new niche can be carved out.

The study, Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability, identifies the full set of activities that NPP groups perform across the development cycle as well as the structure and roles of NPP groups. The research examines dozens of NPP developmental activities in terms of timing during the development process, intended outcomes and value for the organization. In addition, the study details the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolve as a company matures.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies. The research report reflects the current state of New Product Planning efforts at best-in-class organizations such as Abbott, Astellas, Bayer, Daiichi Sankyo, Eli Lilly, Merck, Novartis, sanofi-aventis, Wyeth and others.

To download a complimentary sample of this study, please click: http://www3.best-in-class.com/rr993.htm.    

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 

SOURCE Best Practices, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED